Since then, immunotherapy has made great progress, especially in immune checkpoint blockades of cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 (PD-1) in melanoma (Hodi et al., 2010; Robert et al., 2015) and other cancers (Zou et al., 2016). The gene discussed is PDCD1; the disease is cancer.